Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Non-cash Items: 2012-2025

Historic Non-cash Items for Lineage Cell Therapeutics (LCTX) over the last 9 years, with Sep 2025 value amounting to $7.5 million.

  • Lineage Cell Therapeutics' Non-cash Items fell 21.05% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year decrease of 21.05%. This contributed to the annual value of $8.2 million for FY2024, which is 683.19% up from last year.
  • Lineage Cell Therapeutics' Non-cash Items amounted to $7.5 million in Q3 2025, which was up 88,135.29% from $8,500 recorded in Q2 2025.
  • Lineage Cell Therapeutics' 5-year Non-cash Items high stood at $12.9 million for Q1 2022, and its period low was $8,500 during Q2 2025.
  • Moreover, its 3-year median value for Non-cash Items was $9.3 million (2023), whereas its average is $7.2 million.
  • Per our database at Business Quant, Lineage Cell Therapeutics' Non-cash Items skyrocketed by 76,521.51% in 2021 and then slumped by 99.92% in 2025.
  • Over the past 5 years, Lineage Cell Therapeutics' Non-cash Items (Quarterly) stood at $6.4 million in 2021, then crashed by 78.66% to $1.4 million in 2022, then decreased by 23.24% to $1.0 million in 2023, then skyrocketed by 683.19% to $8.2 million in 2024, then dropped by 21.05% to $7.5 million in 2025.
  • Its last three reported values are $7.5 million in Q3 2025, $8,500 for Q2 2025, and $9,700 during Q1 2025.